Last updated: Nov 27, 2025
Our expert analysis reveals the rise of new leaders, the repositioning of established players, and the emergence of fresh competitors entering the scene.
Foreword
Welcome to Generics Bulletin’s 2024 ranking of the Top 50 generics and biosimilars firms. This eBook offers a comprehensive overview of the leading companies in the industry, highlighting the significant shifts and trends that have shaped the generics and biosimilars landscape over the past year. From a familiar yet evolving Top 10 to notable changes throughout the rankings, we delve deeper into the strategic moves, market dynamics, and financial performance that provides a complete picture of the off-patent pharmaceutical sector.
Our analysis reveals the rise of new leaders, the repositioning of established players, and the emergence of fresh competitors entering the scene. By compiling and explaining all the data from our 2024 rankings, Generics Bulletin provides a valuable resource for industry professionals, investors, and stakeholders to understand the current state of the market, identify key trends, and gain insights into the strategies driving success in the generics and biosimilars industry.
Read more..
